cafepharma
@cafepharma.bsky.social
The original site for employees in pharma, medical, and diagnostic sales and related industries. Join us and stay informed.
Tue news: Novo amycretin success in mid-stage diabetes trial. Promising late-stage data for JNJ myeloma combo. Avidity played hardball to land Novartis. More Medicare drug price negotiations. Gilead’s biobucks TREX1 deal. —https://bit.ly/3JeBlY5
November 25, 2025 at 5:10 PM
Tue news: Novo amycretin success in mid-stage diabetes trial. Promising late-stage data for JNJ myeloma combo. Avidity played hardball to land Novartis. More Medicare drug price negotiations. Gilead’s biobucks TREX1 deal. —https://bit.ly/3JeBlY5
Mon news: Novo Alzheimer’s drug trials fail. Solventum to buy Acera Surgical. JNJ abandons Alzheimer’s antibody. Biotech CEOs’ letter to Makary. Bayer blood thinner trial win. —https://bit.ly/3JeBlY5
November 24, 2025 at 6:46 PM
Mon news: Novo Alzheimer’s drug trials fail. Solventum to buy Acera Surgical. JNJ abandons Alzheimer’s antibody. Biotech CEOs’ letter to Makary. Bayer blood thinner trial win. —https://bit.ly/3JeBlY5
Fri news: Novo, Lilly to sell obesity drugs directly to employers. AnaptysBio-GSK legal tussle. Big Pharma employees rate their CEOs. House Dems introduce new drug price negotiation bill. Lilly market cap nears $1T. —https://bit.ly/3JeBlY5
November 21, 2025 at 5:11 PM
Fri news: Novo, Lilly to sell obesity drugs directly to employers. AnaptysBio-GSK legal tussle. Big Pharma employees rate their CEOs. House Dems introduce new drug price negotiation bill. Lilly market cap nears $1T. —https://bit.ly/3JeBlY5
Thurs news: ABT to acquire Exact Sciences for about $21B. Novo GLP-1 Alzheimer’s study. Regeneron’s Eyelid HD gets two FDA nods in one day. Moderna’s $1.5B loan. Madrigal’s patient-centric MASH strategy. —https://bit.ly/3JeBlY5
November 20, 2025 at 4:35 PM
Thurs news: ABT to acquire Exact Sciences for about $21B. Novo GLP-1 Alzheimer’s study. Regeneron’s Eyelid HD gets two FDA nods in one day. Moderna’s $1.5B loan. Madrigal’s patient-centric MASH strategy. —https://bit.ly/3JeBlY5
Wed news: After Lundbeck's surprise bid, Alkermes sweetens deal to acquire Avadel. Pfizer wins $41.5M settlement over ADHD drug. Merck HIV therapy matches Gilead’s. Sackler/Purdue Pharma settlement plan gets judge approval. RNAi biotech Arrowhead wins first FDA approval. —https://bit.ly/3JeBlY5
November 19, 2025 at 5:10 PM
Wed news: After Lundbeck's surprise bid, Alkermes sweetens deal to acquire Avadel. Pfizer wins $41.5M settlement over ADHD drug. Merck HIV therapy matches Gilead’s. Sackler/Purdue Pharma settlement plan gets judge approval. RNAi biotech Arrowhead wins first FDA approval. —https://bit.ly/3JeBlY5
Mon news: JNJ buys Halda for cancer assets. Novo slashing out-of-pocket prices for Ozempic and Wegovy. Lilly bets $2.6B+ for a bispecific antibody platform. BMS and JNJ dump ACS drug milvexian. Labcorp buying Parkview Health outreach lab assets. —https://bit.ly/3JeBlY5
November 17, 2025 at 5:33 PM
Mon news: JNJ buys Halda for cancer assets. Novo slashing out-of-pocket prices for Ozempic and Wegovy. Lilly bets $2.6B+ for a bispecific antibody platform. BMS and JNJ dump ACS drug milvexian. Labcorp buying Parkview Health outreach lab assets. —https://bit.ly/3JeBlY5
Fri news: Merck buys Cidara and its flu antiviral. Pfizer to divest BioNTech stake. BMS/JNJ blood thinner flunks phase 3. Lundbeck tries to outbid Alkermes for Avadel. Novo shareholders approve new chair. —https://bit.ly/3JeBlY5
November 14, 2025 at 4:32 PM
Fri news: Merck buys Cidara and its flu antiviral. Pfizer to divest BioNTech stake. BMS/JNJ blood thinner flunks phase 3. Lundbeck tries to outbid Alkermes for Avadel. Novo shareholders approve new chair. —https://bit.ly/3JeBlY5
Thurs news: Gilead preps to file bictegravir/lenacapavir combo. Metsera shareholders vote yes to Pfizer. Who’s who in the lucrative I&I space. Novo faces rare shareholder rebuke. FDA unveils new regulatory roadmap for bespoke therapies. —https://bit.ly/3JeBlY5
November 13, 2025 at 5:12 PM
Thurs news: Gilead preps to file bictegravir/lenacapavir combo. Metsera shareholders vote yes to Pfizer. Who’s who in the lucrative I&I space. Novo faces rare shareholder rebuke. FDA unveils new regulatory roadmap for bespoke therapies. —https://bit.ly/3JeBlY5
Wed news: Bayer earnings and cancer clear-out. Medtech VC funding slowed in Q3. Alkermes narcolepsy trial. Sandoz expects to enter Ozempic biosims in Canada early ’26. FDA names Pazdur as new CDER director. —https://bit.ly/3JeBlY5
November 12, 2025 at 5:35 PM
Wed news: Bayer earnings and cancer clear-out. Medtech VC funding slowed in Q3. Alkermes narcolepsy trial. Sandoz expects to enter Ozempic biosims in Canada early ’26. FDA names Pazdur as new CDER director. —https://bit.ly/3JeBlY5
Tue news: Novo’s mixed ATTR-CM data. Novo cutting India Wegovy price. Mallinckrodt rebrand. AZ stock record high. Neurocrine depression drug failure. —https://bit.ly/3JeBlY5
November 11, 2025 at 5:21 PM
Tue news: Novo’s mixed ATTR-CM data. Novo cutting India Wegovy price. Mallinckrodt rebrand. AZ stock record high. Neurocrine depression drug failure. —https://bit.ly/3JeBlY5
Mon news: Lilly in $1.2B RNAi pact with Sanegene. Lilly’s Insilico AI R&D pact. AZ phase 3 blood pressure win. Roche MS hope has phase 3 win. Pfizer wins Metsera bidding war. —https://bit.ly/3JeBlY5
November 10, 2025 at 5:12 PM
Mon news: Lilly in $1.2B RNAi pact with Sanegene. Lilly’s Insilico AI R&D pact. AZ phase 3 blood pressure win. Roche MS hope has phase 3 win. Pfizer wins Metsera bidding war. —https://bit.ly/3JeBlY5
Fri news: How weight loss drug price cuts will affect American users. Lilly’s Mounjaro now top selling drug in India. Gilead breast cancer drug trial fail. FDA’s 2nd round of priority vouchers. Intellia shares fall after CRISPR patient dies. —https://bit.ly/3JeBlY5
November 7, 2025 at 5:42 PM
Fri news: How weight loss drug price cuts will affect American users. Lilly’s Mounjaro now top selling drug in India. Gilead breast cancer drug trial fail. FDA’s 2nd round of priority vouchers. Intellia shares fall after CRISPR patient dies. —https://bit.ly/3JeBlY5
Thurs news: AZ quarter revenue hits new height. Lilly amylin agonist heads to phase 3. Novartis radiopharma success. New indication for JNJ’s Caplyta. Novartis in Super Bowl 2026. —https://bit.ly/3JeBlY5
November 6, 2025 at 6:13 PM
Thurs news: AZ quarter revenue hits new height. Lilly amylin agonist heads to phase 3. Novartis radiopharma success. New indication for JNJ’s Caplyta. Novartis in Super Bowl 2026. —https://bit.ly/3JeBlY5
Wed news: Novo’s new CEO on earnings. Is Metsera worth the fuss? Amgen halts gastric cancer trial. Bravehart Bio launches. Pfizer pipeline cuts. —https://bit.ly/3JeBlY5
November 5, 2025 at 5:17 PM
Wed news: Novo’s new CEO on earnings. Is Metsera worth the fuss? Amgen halts gastric cancer trial. Bravehart Bio launches. Pfizer pipeline cuts. —https://bit.ly/3JeBlY5
Mon news: Kimberly Clark buying Tylenol owner Kenvue for more than $40B. AZ, Lilly, Merck commit $120M to Virginia pharma training. Tariffs, pricing, backroom deals. FDA director's admin leave sparks controversy. Pfizer sues Metsera and Novo. —https://bit.ly/3JeBlY5
November 3, 2025 at 5:31 PM
Mon news: Kimberly Clark buying Tylenol owner Kenvue for more than $40B. AZ, Lilly, Merck commit $120M to Virginia pharma training. Tariffs, pricing, backroom deals. FDA director's admin leave sparks controversy. Pfizer sues Metsera and Novo. —https://bit.ly/3JeBlY5
Fri news: Lilly weight loss drug will be candidate for new FDA speedy approval program. Pfizer may hold Trump card in Metsera bid. Gilead ends HIV trial. Merck vaccine sales drop. Biogen-Neurocrine-Alnylam earnings. —https://bit.ly/3JeBlY5
October 31, 2025 at 4:33 PM
Fri news: Lilly weight loss drug will be candidate for new FDA speedy approval program. Pfizer may hold Trump card in Metsera bid. Gilead ends HIV trial. Merck vaccine sales drop. Biogen-Neurocrine-Alnylam earnings. —https://bit.ly/3JeBlY5
Thurs news: Novo-Pfizer bidding war for Metsera. Lilly blows past estimates. BMS earnings. Zimmer gets breakthrough status for iodine-treated hip replacement. How Trump pharma agenda is impacting CEO chatter. —https://bit.ly/3JeBlY5
October 30, 2025 at 4:11 PM
Thurs news: Novo-Pfizer bidding war for Metsera. Lilly blows past estimates. BMS earnings. Zimmer gets breakthrough status for iodine-treated hip replacement. How Trump pharma agenda is impacting CEO chatter. —https://bit.ly/3JeBlY5
Wed news: GSK earnings. Lilly-Walmart Zepbound access. GE Healthcare revenue growth. What is next for Novo? Lilly-Nvidia pharma supercomputer. —https://bit.ly/3JeBlY5
October 29, 2025 at 4:17 PM
Wed news: GSK earnings. Lilly-Walmart Zepbound access. GE Healthcare revenue growth. What is next for Novo? Lilly-Nvidia pharma supercomputer. —https://bit.ly/3JeBlY5
Mon news: Novartis shares slip on $12B deal to buy Avidity. Innocent/Lilly’s mazdutide beats Novo in head-to-head. MapLight IPO to fund BMS competitor. Organon CEO resigns amid internal investigation. Intellia plummets on paused trial. —https://bit.ly/3JeBlY5
October 27, 2025 at 4:07 PM
Mon news: Novartis shares slip on $12B deal to buy Avidity. Innocent/Lilly’s mazdutide beats Novo in head-to-head. MapLight IPO to fund BMS competitor. Organon CEO resigns amid internal investigation. Intellia plummets on paused trial. —https://bit.ly/3JeBlY5
Thurs news: Roche shares fall as new drug sales disappoint. How JNJ kept growing amid Stelara erosion. Mass biotech hub is limping. Moderna CMV vax fails key study. JNJ sponsoring NY Jets. —https://bit.ly/3JeBlY5
October 23, 2025 at 3:34 PM
Thurs news: Roche shares fall as new drug sales disappoint. How JNJ kept growing amid Stelara erosion. Mass biotech hub is limping. Moderna CMV vax fails key study. JNJ sponsoring NY Jets. —https://bit.ly/3JeBlY5
Wed news: Takeda in huge biobucks+$1.2B deal with Innovent. How Novo’s board bust-up will sharpen US focus. US pharma price probe raises threat of new tariffs. Alkermes to enter sleep market with Avadel buy. Intuitive Surgical earnings beat. —https://bit.ly/3JeBlY5
October 22, 2025 at 4:41 PM
Wed news: Takeda in huge biobucks+$1.2B deal with Innovent. How Novo’s board bust-up will sharpen US focus. US pharma price probe raises threat of new tariffs. Alkermes to enter sleep market with Avadel buy. Intuitive Surgical earnings beat. —https://bit.ly/3JeBlY5
The Novo Nordisk message board has been our top-traffic board for weeks now, and today’s mass boardroom shakeup has only made for further activity: cafepharma.com/boards/forum...
Novo Nordisk
Anonymous board for Novo Nordisk
cafepharma.com
October 21, 2025 at 4:33 PM
The Novo Nordisk message board has been our top-traffic board for weeks now, and today’s mass boardroom shakeup has only made for further activity: cafepharma.com/boards/forum...